GSK Pharma: Eyeing 2005 - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

GSK Pharma: Eyeing 2005

Mar 13, 2003

MNC Pharma major, GlaxoSmithKline (GSK), has reported encouraging profit growth numbers for the December quarter as well as the full year 2002. However, the topline growth was staid, owing to sluggishness in allied businesses like animal healthcare, fine chemicals and exports.

(Rs m) 4QFY02 4QFY03 Change FY02 FY03 Change
Net Sales 2,623 2,133 -18.7% 10,103 10,473 3.7%
Other Income 54 106 97.0% 278 338 21.6%
Total expenditure 2,355 1,923 -18.3% 9,057 8,736 -3.6%
Operating Profit (EBDIT) 268 209 -21.8% 1,046 1,737 66.1%
Operating Profit Margin (%) 10.2% 9.8%   10.4% 16.6%  
Interest (net) -19 -33 - -89 -83 -
Depreciation 109 46 -57.6% 257 195 -24.1%
Profit before Tax 232 302 30.3% 1,156 1,963 69.9%
Extraordinary items -527 -251 - -313 -304 -
Tax 109 77 -29.8% 403 679 68.6%
Profit after Tax/(Loss) -404 -26 - 440 981 123.0%
Effective tax rate (%) 47.0% 25.3%   34.8% 34.6%  
Net profit margin (%) -15.4% -1.2%   4.4% 9.4%  
No. of Shares (eoy) (m) 74.5 74.5   74.5 74.5  
Earnings per share* -21.7 -1.4   5.9 13.2  
Current P/e ratio         22.4  

Its core business of pharmaceuticals (over 80% of sales) reported over 8.5% growth during the year, in line with the industry trend. The allied businesses recorded a drop of over 7% in sales during the year. Consequently, GSK finished FY03 with sub 4% topline growth (excluding excise). The performance in December quarter was even worse, as topline dipped nearly 19% YoY.

What GSK lost in topline terms, it made up by increasing efficiencies and hence operating margins. In FY03, operating margins improved by over 6% at 16.6%. As per the management, the improvement in margins is likely to continue as GSK has decided to concentrate on select profitable brands (i.e. not under DPCO), in a bid to give a fillip to its profitability. One would have thought that GSK is adopting the model adopted by many FMCG companies recently.

Cost break-up
(Rs m) 4QFY02 4QFY03 Change FY02 FY03 Change
Raw material 1,432 1,017 -29.0% 5,311 5,031 -5.3%
Staff cost 291 350 20.2% 1,311 1,313 0.1%
Other expenditure 661 570 -13.8% 2,572 2,491 -3.1%
Recovery of expenses (29) (13) -55.9% (136) (100) -26.9%
Total 2,355 1,923 -18.3% 9,057 8,736 -3.6%

Post the merger with SmithKline, GSK has increasing looked to close down unviable plants and looked to increasing outsource manufacturing. Its looking at selling of property (of erstwhile SmithKline) and streamlining operations of both companies for optimal utilisation (through VRS). Consequently, the company's depreciation provisioning has come down quite significantly and the spurt in other income suggests that it is reaping the benefits of investible funds.

Extraordinary items break-up
(Rs m) FY02 FY03
VRS and other retirement benefits (959) (312)
Loss/write off of fixed assets (35) (36)
Merger/rationalisation expenses (122) (51)
Increase in retirment benefit contribution - (90)
Profit on sale of plant and property 394 71
Taxes on the above 409 114
Total (313) (304)

Excluding extraordinary items, GSK would have reported 84% growth in net profits during the December quarter, and 71% growth in FY03. The details of these extraordinary items are given in the table above.

At the current price of Rs 296, the stock is trading at 22.4x FY03 earnings. The company is gearing itself towards 2005, when patent regime comes into force. The valuations look quite attractive seeing the company's focus and the strong brand name.

Equitymaster requests your view! Post a comment on "GSK Pharma: Eyeing 2005". Click here!


More Views on News

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 30, 2020 02:57 PM


  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks